B-cell receptor recognizing HIV-1 clade C envelope glycoprotein epitopes (BCR (HIV-1 Clade C Env))

The B-cell receptor (BCR) recognizing HIV-1 clade C envelope (Env) epitopes is a specialized surface immunoglobulin that mediates the immune recognition of the most widespread HIV-1 subtype (Haynes et al., 2012, Nature Medicine). These receptors are the primary focus of germline-targeting vaccine strategies, which aim to activate specific B-cell lineages capable of evolving into broadly neutralizing antibodies (bnAbs) (Schief et al., 2015, Science). Clade C HIV-1 is particularly significant due to its high prevalence in sub-Saharan Africa and India, making the elicitation of BCRs that can neutralize this variant a global health priority. The interaction between the BCR and the HIV-1 Env protein involves complex recognition of epitopes such as the CD4 binding site, the V1V2 apex, and the MPER region (Doria-Rose et al., 2014, Nature). Therapeutic interventions, primarily in the form of experimental vaccines like eOD-GT8, seek to precisely engage these BCRs to overcome the virus's extensive glycan shielding and structural diversity (Jardine et al., 2013, Science). Successful activation and maturation of these B-cell populations are considered essential for the development of a preventative HIV vaccine.

Other names

HIV-1 Clade C Env-specific B-cell receptorAnti-HIV-1 Clade C BCRClade C Env-binding BCRHIV-1 Clade C Envelope-specific B-cell receptor

Vaccine immunogens act as agonists that bind to and cross-link specific B-cell receptors, triggering intracellular signaling cascades that lead to B-cell proliferation, affinity maturation through somatic hypermutation, and differentiation into memory B cells or antibody-secreting plasma cells (Kousiappa et al., 2023, Vaccines).